GOTHIC 1

Status: Completed

Location: United Kingdom

Division:  At-Risk Mental State (ARMS), Schizophrenia Spectrum and Other Psychosis Disorder

Themes:

  • Psychological Medicine & Clinical Trials
  • Severe Mental Illness Including Psychosis
  • Psychopharmacology


Summary:
 A UK-based, multicentre, randomised, double-blind, placebo-controlled feasibility trial (42 patients) assessing Glycopyrrolate vs. placebo for treating Clozapine-Induced Hypersalivation (CIH).

Description: The Problem: Clozapine-Induced Hypersalivation (CIH) affects up to 80% of patients taking Clozapine for conditions like schizophrenia. It is a debilitating side effect causing profound social stigma, embarrassment, lowered self-esteem, and social isolation, potentially impacting treatment adherence.

The Intervention & Objectives: GOTHIC 1 was a feasibility trial conducted across Lancashire and Merseyside, UK, recruiting 42 community care patients experiencing CIH. Its objectives were to assess the feasibility of recruitment, the acceptability of the interventions, and likely attrition rates and tolerability for a future main trial. The trial compared Glycopyrrolate (an anti-muscarinic) against placebo, as a potential alternative to Hyoscine Hydrobromide (which has limited evidence).

Method: The study lasted 5 weeks (1-week wash-out, 4-week treatment). Participants were randomised to one of three arms (details not specified in the document, likely Glycopyrrolate dose vs. placebo). Self-report measures of salivation and side effects were taken weekly, with cognitive measures assessed twice.

Conclusion & Impact: The management of debilitating side effects like CIH is crucial for improving Clozapine adherence. While Hyoscine Hydrobromide is commonly used, this study explored the promising evidence for Glycopyrrolate, which may be more successful and cause fewer cognitive side effects. The results of this feasibility trial were intended to inform the design of a larger, definitive study.

Key Publications:

  • A multi-centre, randomised, double-blind, placebo-controlled feasibility trial of Glycopyrrolate for Clozapine-induced hypersalivation (Link: https://pubmed.ncbi.nlm.nih.gov/27871302/)